Evidence mapPaperPMID 41557957Full record

ArticleHuman vaccines & immunotherapeutics2026

Vaccine expression systems and maternal/neonatal factors: Impacts on hepatitis B immunization efficacy in preterm infants.

Lu Shen, Yan Xie, Zhongkui Zhu, Jintao Wang, Yunke Qian, Huaxian Liu, Yang Yu, Wanqin Tang

Erratum issuedAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Lu ShenDepartment of Expanded Programme on Immunization, Taizhou City Center for Disease Control and Prevention, Taizhou, Jiangsu, China.
Yan XieDepartment of Expanded Programme on Immunization, Taizhou City Center for Disease Control and Prevention, Taizhou, Jiangsu, China.
Zhongkui ZhuDepartment of Expanded Programme on Immunization, Taizhou City Center for Disease Control and Prevention, Taizhou, Jiangsu, China.
Jintao WangDepartment of Expanded Programme on Immunization, Taizhou City Center for Disease Control and Prevention, Taizhou, Jiangsu, China.
Yunke QianDepartment of Expanded Programme on Immunization, Taizhou City Center for Disease Control and Prevention, Taizhou, Jiangsu, China.
Huaxian LiuDepartment of Expanded Programme on Immunization, Taizhou City Center for Disease Control and Prevention, Taizhou, Jiangsu, China.
Yang YuDepartment of Expanded Programme on Immunization, Taizhou City Center for Disease Control and Prevention, Taizhou, Jiangsu, China.
Wanqin TangDepartment of Expanded Programme on Immunization, Taizhou City Center for Disease Control and Prevention, Taizhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The global rise in preterm infants presents specific challenges for hepatitis B prevention. Although hepatitis B vaccination is recommended, detailed understanding of immunogenicity patterns and influencing factors requires further investigation. We analyzed 699 preterm infants completing the hepatitis B vaccination series to assess immunogenicity via geometric mean concentration (GMC) and seroprotection rate (SPR). The regimen was highly immunogenic, with an overall SPR of 99.43% (GMC: 986.36 mIU/mL) and 95.28% of infants achieving high-level protection (anti-HBs ≥100 mIU/mL). Though SPR was consistently high across subgroups, notable GMC variations emerged: infants with gestational age <28 weeks markedly higher GMC (3,735.59 mIU/mL) than more mature subgroups. Statistically significant GMC differences were noted between immunization protocols, with uniform schedules yielding higher values (1,281.26 mIU/mL) than mixed approaches (691.91 mIU/mL;

Indexed as

Hepatitis BHepatitis B AntibodiesHepatitis B VaccinesInfant, PrematureVaccine EfficacyAdultFemaleHepatitis B Surface AntigensHumansImmunization ScheduleImmunogenicity, VaccineInfantInfant, NewbornMalePregnancyVaccinationHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B Vaccineshepatitis B vaccineimmunogenicityPreterm infantsseroprotection rate

Identifiers

PMID41557957
PMCPMC12826699

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.